Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2009-017082-39Phase 2Terminated
Phase 2, randomised, double-blind trial of cinaciguat in chronic heart failure (CHF) and heart failure (HF) (4 arms), sponsored by Bayer. Primary endpoint: Change from baseline to 8 hours on Dyspnea VAS. Started Dec 2009; status: terminated.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2009-017082-39.